MEK162 is also evaluated in combination with third generation cyclin dependent kinases 4 and 6 (CDK4/6) inhibitor, Ribociclib (LEE001), showing increased antitumour activity and safety in advanced NRAS and BRAF mutated melanoma [41]. This evidence concerns the gene NRAS and melanoma.